School of Medicine
Showing 1-10 of 81 Results
Saul A. Rosenberg, MD, Professor of Lymphoma
Current Research and Scholarly Interests Clinical investigation in Hodgkin's disease, non-Hodgkin's Lymphomas and cutaneous lymphomas. Experimental therapeutics with novel chemotherapy and biologically targeted therapies.
The research program is highly collaborative with radiation oncology, industry, pathology and dermatology.
Ash A. Alizadeh, MD/PhD
Associate Professor of Medicine (Oncology)
Current Research and Scholarly Interests My research is focused on attaining a better understanding of the initiation, maintenance, and progression of tumors, and their response to current therapies toward improving future treatment strategies. In this effort, I employ tools from functional genomics, computational biology, molecular genetics, and mouse models.
Clinically, I specialize in the care of patients with lymphomas, working on translating our findings in prospective cancer clinical trials.
Douglas W. Blayney
Professor of Medicine (Oncology) at the Stanford University Medical Center
Current Research and Scholarly Interests Improving the quality of cancer care at Stanford, in our network of care, and nationally
Nam Quoc Bui
Clinical Assistant Professor, Medicine - Oncology
Bio Dr. Bui is a Clinical Assistant Professor of Medicine at the Stanford Cancer Institute and a specialist in the Sarcoma and Developmental Therapeutics programs. Dr. Bui earned an undergraduate degree in Computer Science at Stanford University and went on to earn his medical degree from the University of Texas Southwestern Medical Center. He completed Internal Medicine residency at Stanford Hospital and Hematology/Oncology fellowship at the University of California San Diego, where he performed extensive research in bioinformatics to analyze tumor sequencing data. His research background and interests are in the field of bioinformatics as applied to large data sets and the study of novel compounds in rare malignancies.
Robert W. Carlson
Professor of Medicine (Oncology and General Internal Medicine/Medical Informatics) at the Stanford University Medical Center, Emeritus
Current Research and Scholarly Interests Clinical investigations in breast cancer include institutional and NSABP studies of chemoprevention, adjuvant therapy, psychosocial interventions, treatment of metastatic disease, methods of decreasing anthracycline cardiotoxicity, and modulation of multidrug resistance. Research in meta-analysis includes the performance of meta-analysis in a wide variety of settings in cancer treatment by the international Meta-Analysis Group in Cancer.
Instructor, Medicine - Oncology
Current Research and Scholarly Interests My research is on the translational application of next-generation sequencing technologies to breast cancer care: (1) the value of hereditary cancer genetic panel testing in clinical practice, (2) the mechanisms by which inherited genetic variants lead to breast cancer development, and (3) the analysis of somatic tumor sequencing data to inform understanding of breast tumorigenesis, metastasis, and development of resistance in response to therapeutics.
Christopher T Chen, MD
Clinical Instructor, Medicine - Oncology
Bio Dr. Chen is a board-certified, fellowship-trained specialist in oncology and hematology. He is also a Clinical Instructor in the Division of Oncology in the Department of Medicine at Stanford University School of Medicine.
Dr. Chen delivers comprehensive, compassionate care for the complete spectrum of cancer patients. As a researcher, he focuses on patient, practice, and population health management issues.
At Massachusetts General Hospital, he received the Ruth L. Kirchstein-National Service Research Award in Cancer Biology for his work exploring the molecular structure of metastatic solid tumors. At the Dana-Farber Cancer Institute, he was an investigator and translational researcher focused on developing first-in-class therapeutics for tumors.
With the Centers for Medicare & Medicaid Services, he helped lead regulatory reform of skilled nursing facilities. As a Center for Health Policy fellow with the Brookings Institution, he led a study with FDA, Medicare, and pharmaceutical industry officials on the impact of generic biologic drugs on access, cost, and innovation.
Journal articles co-authored by Dr. Chen have addressed topics including oncology drug pricing, fee-for-service accountability, and Medicare spending for cancer patients. His work has appeared in the New England Journal of Medicine, JAMA, Journal of Oncology Practice, Science Advances, and Health Services Research. He has contributed to the Harvard Business Review and to the chapter on targeted therapies for gastrointestinal cancers in the May 2020 ASCO Educational Book.
He has presented the findings of his research at the Centers for Medicare & Medicaid Services Annual Pioneer ACO Conference and at meetings of the Society of Hospital Medicine, European Society for Medical Oncology, and California Department of Health Services.
Dr. Chen has earned recognition from the Society for Hospital Medicine and Harvard University, where he studied molecular and cellular biology as an undergraduate. From Washington University, his medical school alma mater, he received the Dr. Richard S. Brookings Medical School Prize for research achievements and the Dr. William Rubenstein Award in Medicine for clinical excellence.
Dr. Chen is a member of the American Society of Clinical Oncology and European Society for Medical Oncology. He is an associate member of the American Association for Cancer Research. He has volunteered as the Vice Chair of the American Red Cross National Youth Council.
Curtis R. Chong, MD, PhD, MPhil, FACP
Clinical Assistant Professor, Medicine - Oncology
Bio Dr. Chong was recruited to Stanford from the Memorial Sloan Kettering (MSK) Cancer Center, where he led MSK's launch of the early drug development and immunotherapy clinical trials program in New Jersey. At MSK, Dr. Chong was a member of the gastrointestinal oncology service and was one of two MSK physicians in New Jersey who specialized in treating melanoma. Prior to joining MSK, Dr. Chong was a member of the thoracic oncology service at the Dana-Farber Cancer Institute and an attending physician at the Massachusetts General Hospital and Brigham and Women's Hospital, all ailiates of Harvard Medical School.
Dr. Chong completed his categorical residency in internal medicine at the Massachusetts General Hospital/Harvard Medical School, his oncology fellowship at the Dana-Farber Cancer Institute, and is board-certified in internal medicine and medical oncology. He has received research support from the American Society of Clinical Oncology (Young Investigator Award), Uniting Against Lung Cancer, and the American Cancer Society. Dr. Chong has been published in the New England Journal of Medicine, Nature, Nature Medicine, Nature Chemical Biology, JAMA Oncology, and his research on drug discovery has been featured in the New York Times and Popular Science.
Born and raised in Honolulu where he attended public schools, Dr. Chong sang in the Honolulu Boy Choir, and was the 1993 Honolulu Star Bulletin Newspaper Boy of the Year. He received his A.B. in biochemical sciences from Harvard University magna cum laude followed by an M.Phil. in Chemistry with Sir Alan Fersht at the University of Cambridge (Emmanuel College). He then received his MD and PhD in pharmacology from The Johns Hopkins University School of Medicine.
An intrepid traveler and avid long-distance runner, Dr. Chong has visited 54 countries and completed 126 marathons in all 50 states, 18 countries, and 6 on continents.